Tumor testing can lead to different treatment choices and better outcomes.
Testing all cases of colon cancer for the presence of microsatellite instability (MSI) is currently a national and international goal, said Thomas K. Weber, M.D., FACS, president of the Colon Cancer Foundation.
Testing patients for biomarkers such as MSI status and Lynch syndrome can have treatment implications that ultimately lead to improved outcomes
